Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib For Treatment Of Chronic Pouchitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects ages 18 to 80~2. Subjects with a history of proctocolectomy with ileal pouch anal anastomosis (IPAA) for UC at least 6 months prior to screening.~3. Subjects with pouchitis that is chronic, defined by a mPDAI score ≥5 assessed as the average from 3 days immediately prior to the baseline study visit and a minimum endoscopic sub-score of 2 (outside the staple or suture line) with either (a) ≥ 3 recurrent episodes within 1 year prior to the screening treated with ≥2 weeks of antibiotic or other prescription therapy, (b) requiring maintenance antibiotic therapy taken continuously for ≥4 weeks immediately prior to the baseline study visit~4. Women of childbearing potential must have documentation of a negative pregnancy test at screening and must agree to use two highly effective methods of birth control during the study and for at least 1 month after completion of study drug dosing.~Exclusion Criteria:~1. Subjects with IPAA surgery done for Crohn's disease (CD) or familial adenomatous polyposis (FAP) indications.~2. Subjects with primary CD of pouch, isolated or predominant cuffitis or mechanical complications of the ileal pouch.~3. Subjects with prior exposure to tofacitinib.~4. Subjects with a diverting stoma.~5. Subjects with a prior history or risk factors for venous thromboembolism.~6. Subjects with active bacterial, parasitic, fungal, mycobacterial, or viral infection.~7. Subjects with a history of latent or active tuberculosis.~8. Subjects positive for hepatitis B virus (HBV) surface antigen, hepatitis B virus core antibody with a negative hepatitis B surface antibody or with detectable serum hepatitis B DNA.~9. Female subjects who are pregnant or lactating.~10. Female subjects of childbearing potential who are sexually active and do not agree to using two highly effective methods of contraception during the study period.~11. Subjects with clinically significant laboratory abnormalities at study screening.~    * Other eligibility criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Chronic pouchitis (Type: EXPERIMENTAL): This arm will include subjects with chronic pouchitis and will receive tofactinib 10 mg twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).